MK0594

Vyne Therapeutics Inc. · Phase 2 active Small molecule

At a glance

Generic name	MK0594
Sponsor	Vyne Therapeutics Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of MK0594 in Patients With Alcohol Dependence (0594-020) (PHASE2)
Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MK0594 CI brief — competitive landscape report
MK0594 updates RSS · CI watch RSS
Vyne Therapeutics Inc. portfolio CI